- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/06 - Antianaemics
Patent holdings for IPC class A61P 7/06
Total number of patents in this class: 1738
10-year publication summary
|
43
|
93
|
86
|
101
|
130
|
151
|
118
|
133
|
94
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 349 |
40 |
| Agios Pharmaceuticals, Inc | 221 |
36 |
| Daiichi Sankyo Company, Limited | 1878 |
27 |
| Global Blood Therapeutics, Inc. | 181 |
26 |
| Vifor (International) AG | 140 |
20 |
| The Children's Hospital of Philadelphia | 822 |
18 |
| Keros Therapeutics, Inc. | 71 |
18 |
| Children's Medical Center Corporation | 1913 |
17 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3072 |
14 |
| Akebia Therapeutics, Inc. | 120 |
13 |
| Takeda Pharmaceutical Company Limited | 2710 |
12 |
| Epizyme, Inc. | 367 |
12 |
| Pharmacosmos Holding A/S | 202 |
12 |
| Novartis AG | 10500 |
11 |
| Assistance Publique-hopitaux de Paris (aphp) | 539 |
11 |
| Sunshine Lake Pharma Co., Ltd. | 611 |
11 |
| Université Paris Cité | 864 |
11 |
| The Regents of the University of California | 20339 |
10 |
| Amgen Inc. | 4286 |
10 |
| FibroGen, Inc. | 135 |
10 |
| Other owners | 1399 |